Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

26.45 +0.40 (+1.54%)

Streaming Delayed Price Updated: 1:24 PM EST, Jan 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

November 21, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

November 17, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

November 15, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis ↗

September 26, 2022

Via Benzinga

Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics ↗

September 08, 2022

Via Benzinga

Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial ↗

November 15, 2022

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.

Via Benzinga

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older

November 15, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗

November 09, 2022

Biotech stocks were hammered Wednesday, including several that had good news.

Via Investor's Business Daily

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

November 08, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 21, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

October 21, 2022

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics ↗

September 22, 2022

Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary ↗

September 09, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022 ↗

September 07, 2022

Upgrades

Via Benzinga

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 23, 2022

Via Benzinga

Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday ↗

September 06, 2022

Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.

Via Benzinga

Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year ↗

August 23, 2022

Arcutis Biotherapeutics (NASDAQ: ARQT) has completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roﬂumilast cream 0.15% in adults and children with Atopic dermatitis (AD).

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 04, 2022

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients...

Via Benzinga

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday ↗

August 04, 2022

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.

Via Benzinga

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session ↗

August 03, 2022

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.

Via Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗

August 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Analyst Ratings for Arcutis Biotherapeutics ↗

August 02, 2022

Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday ↗

August 02, 2022

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

Via Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August ↗

July 29, 2022

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

7 Biotech Stocks to Buy for Q3 ↗

July 18, 2022

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.

Via InvestorPlace

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock ↗

May 26, 2022

Mizuho remains bullish on Arcutis Biotherapeutics Inc (NASDAQ: ARQT). It sees buying opportunity in the weakness as the company heads into 2H of 2022 with four potentially transformative catalysts for...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.